De bespreking van de casus en de analysemethoden is steeds overgenomen van de oorspronkelijke uitgevoerde test. Bedenkt u hierbij dat opmerkingen over analysemethoden en behandelingsadviezen inmiddels verouderd kunnen zijn
| AMPHETAMINES | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| amphetamine | DOA Ronde 11-2 | DOA Ronde 13-1 | DOA 18.3A | |||||||
| dexamphetamine | DOA Ronde 11-4 | DOA Ronde 12-3 | DOA 14.4A | DOA 16.1A | DOA 18.4A | |||||
| methylamphetamine | DOA Ronde 14-3 | DOA 17.2B | ||||||||
| MDA | ||||||||||
| MDEA | DOA Ronde 12-2 | DOA Ronde 14-1 | DOA 15.4B | DOA 16.3B | ||||||
| MDMA | DOA Ronde 11-1 | DOA Ronde 13-1 | DOA 14.4B | DOA 15.3A | DOA 16.2B | DOA 17.2B | ||||
| 4-fluoramfetamine | DOA 17.1B | |||||||||
| methylphenidate | ||||||||||
| BARBITURATES | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| pentobarbital | DOA Ronde 13-3 | DOA 17.3A | ||||||||
| phenobarbital | DOA Ronde 11-2 | |||||||||
| BENZODIAZEPINES | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| alprazolam | DOA Ronde 11-4 | |||||||||
| aminoflunitrazepam | DOA 17.4A | |||||||||
| aminonitrazepam | DOA 17.4A | |||||||||
| chloordiazepoxide | DOA 17.4A | DOA 18.3B | ||||||||
| demoxepam | DOA 18.3A | |||||||||
| desalkylflurazepam | DOA 19.1B | |||||||||
| desmethyldiazepam | DOA 16.1A | |||||||||
| diazepam | DOA Ronde 12-2 | DOA 17.3A | ||||||||
| flunitrazepam | DOA Ronde 10-B | |||||||||
| hydroxyethylflurazepam | DOA 19.1A | |||||||||
| midazolam | DOA 19.2A | |||||||||
| nitrazepam | DOA Ronde 13-2 | DOA 15.3A | ||||||||
| oxazepam | DOA Ronde 10-A | DOA Ronde 12-3 | DOA Ronde 14-2 DOA Ronde 14-3DOA 14.4A |
DOA 18.2B | ||||||
| temazepam | DOA Ronde 14-3 | DOA 17.3A | ||||||||
| COCAÏNE-MET | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| DOA Ronde 10-A | DOA Ronde 11-3 | DOA Ronde 12-1 DOA Ronde 12-2 DOA Ronde 12-4 |
DOA Ronde 13-1 | DOA Ronde 14-2 | DOA 15.2A | DOA 16.2A | DOA 17.2B | DOA 18.2B | DOA 19.1B | |
| ETHANOL | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| ethanol | DOA Ronde 10-A | DOA Ronde 12-2 | DOA 15.1B | DOA 16.1A
DOA 16.4A |
DOA 17.1A | DOA 18.1A | DOA 19.2A | |||
| ethylglucuronide | DOA 16.2A | DOA 17.1A | ||||||||
| FENCYCLIDINE | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| fencyclidine | ||||||||||
| METHADONE | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| DOA Ronde 10-C | DOA Ronde 11-2 DOA Ronde 11-4 |
DOA Ronde 13-2 DOA Ronde 13-4 |
DOA Ronde 14-2 DOA Ronde 14-3 |
DOA 15.3B | DOA 16.4B | DOA 17.2A
DOA 17.4B |
DOA 18.1B
DOA 18.4B |
DOA 19.1A | ||
| OPIATES | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| morphine | DOA Ronde 11-3 | DOA Ronde 12-4 | DOA Ronde 13-1 DOA Ronde 13-2 DOA Ronde 13-4 |
DOA 15.1B | DOA 16.3A
DOA 16.4B |
DOA 17.2A
DOA 17.3A |
DOA 18.2B
DOA 18.3B |
DOA 19.1A | ||
| diacetylmorfine | ||||||||||
| codeïne | DOA Ronde 10-A DOA Ronde 10-C DOA Ronde 10-D |
DOA Ronde 13-3 | DOA 15.2A | |||||||
| hydromorfon | DOA Ronde 11-1 | |||||||||
| 6-MAM | DOA Ronde 13-2 | |||||||||
| oxycodon | DOA Ronde 14-2 | DOA 15.3B | ||||||||
| pholcodine | ||||||||||
| PARACETAMOL | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| paracetamol | DOA 17.1A | DOA 18.1B
DOA 18.3B |
||||||||
| THC | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| DOA Ronde 10-C | DOA Ronde 11-1 DOA Ronde 11-3 |
DOA Ronde 12-2 DOA Ronde 12-3 |
2013 | DOA Ronde 14-1 | DOA 15.1A | DOA 16.1B | DOA 17.1B
DOA 17.2B |
DOA 18.2A
DOA 18.4A |
DOA 19.2A | |
| TRICYCLISCHE ANTIDEPRESSIVA | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| clozapine | DOA 17.3B | |||||||||
| nortriptyline | DOA 17.2A | DOA 18.1B
DOA 18.3A |
||||||||
| OTHER | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| blanko urine | ||||||||||
| buprenorfine | DOA 15.1A | DOA 16.4B | DOA 18.4B | |||||||
| dextropropoxyphen | ||||||||||
| ephedrine | DOA Ronde 10-D | |||||||||
| GBL | DOA 17.4A | |||||||||
| GHB | DOA Ronde 13-4 | DOA Ronde 14-1 | DOA 15.4B | DOA 16.1B
DOA 16.4A |
DOA 17.1B | DOA 18.2A | DOA 19.2B | |||
| glorix | DOA Ronde 12-1 | |||||||||
| ketamine | DOA 18.1A | |||||||||
| LSD | DOA 18.4A | |||||||||
| mephedrone | DOA Ronde 12-3 | |||||||||
| natriumlactaat | DOA 16.4A | |||||||||
| omeprazol | DOA 18.1A | |||||||||
| oxycodon | DOA 17.4B | |||||||||
| PVP (Flakka) | DOA 18.2A | |||||||||
| promethazine | DOA Ronde 13-3 | |||||||||
| quetiapine | DOA Ronde 12-1 | |||||||||
| ranitidine | DOA Ronde 10-A | |||||||||
| shag | ||||||||||
| thee | ||||||||||
| zopiclon |